Emgrast 300 mcg Injection

Introduction of Emgrast 300 mcg Injection

Emgrast 300 mcg Injection is an analogue of the human granulocyte colony-stimulating factor (G-CSF). It stimulates white blood cell growth and helps reduce the risk of infection in patients undergoing chemotherapy for cancer. Patients with blood disorders are advised not to take this medicine.

Emgrast 300 mcg Injection may cause some common adverse effects such as weakness, bone pain, rashes, bone pain, and pain or redness at the site of injection is common. However, inform your doctor if you notice a lump, swelling or bruise that does not go away. It may not protect you from all types of infections, so inform your doctor if you notice fever, chills, rash, sore throat, or swelling of the face or neck.

Many other medicines will interact with this medicine, so please make sure inform to the doctor. Emgrast 300 mcg is not prescribed for breastfeeding and pregnant women. You must use an effective contraceptive during the therapy to avoid pregnancy. Drink adequate fluids to prevent dehydration.

Emgrast 300 mcg Injection is administered by a doctor or nurse at a hospital or clinical setting. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. You should avoid drinking alcohol as it may increase your risk of liver damage. Do not self-administered this Emgrast 300 mcg Injection.

Uses of Emgrast 300 mcg Injection

Patients with Cancer Receiving Myelosuppressive Chemotherapy: Emgrast 300 mcg Injection is used to reduce the incidence of infections manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.

Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy: Emgrast 300 mcg Injection is indicated to shorten the time to neutrophil recovery and duration of fever after induction or consolidation chemotherapy in patients with acute myeloid leukaemia (AML).

Patients with Cancer Undergoing Bone Marrow Transplantation: Emgrast 300 mcg Injection is indicated to shorten the duration of neutropenia and the clinical sequelae associated with neutropenia, ex. febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy, followed by bone marrow transplantation.

Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy: Emgrast 300 mcg Injection is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.

Patients with Severe Chronic Neutropenia: Emgrast 300 mcg Injection is indicated for chronic administration to reduce the frequency and duration of sequelae of severe neutropenia (e.g., fever, infection, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.

Benefits of Emgrast 300 mcg Injection

Emgrast 300 mcg Injection is used to stimulate the production of white blood cells, which play a critical role in the body's immune system. White blood cells help protect the body against infection and disease by attacking and eliminating harmful bacteria and viruses. By increasing the number of white blood cells in the body.

Emgrast 300 mcg may help reduce the risk of infection in people with neutropenia, a condition characterized by a low number of neutrophils, a type of white blood cell.

Emgrast 300 mcg Injection helps reduce the duration of neutropenia and the need for neutropenia-related hospitalizations in people undergoing chemotherapy for cancer. It may also be used to reduce the incidence of febrile neutropenia, a potentially serious complication of chemotherapy that involves fever and low white blood cell counts.

Overall, the main benefit of Emgrast 300 mcg is its ability to help boost the body's immune system and protect against infection.

Side Effects of Emgrast 300 mcg Injection

Like all medications, Emgrast 300 mcg can cause side effects but do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them.

Most Common Side Effects of Emgrast 300 mcg Injection

• Oropharyngeal pain
• Hair loss
• Fatigue
• Diarrhea
• Constipation
• Decreased appetite
• Cough
• Breathing problems
• Injection site reactions (pain, swelling, redness)
  

Common Side Effects of Emgrast 300 mcg Injection

• Bone pain
• Weakness
• Headache
• Rash
• Nausea
• Increased lactate dehydrogenase level in blood
• Vomiting
• Increased uric acid level in the blood
  

How to Use Emgrast 300 mcg Injection?

​​​​Emgrast 300 mcg Injection is administered by a healthcare professional or nurse in a hospital or clinic setting. The specific dosing and administration of Emgrast 300 mcg will depend on the clinical condition of the patient's age and medical history and other factors. Kindly do not self-administer.​

How Emgrast 300 mcg Injection Works?

Emgrast 300 mcg stimulates the production of neutrophil granulocytes, a type of white blood cell that protects the body from infection. This happens by activating cells in the bone marrow called stem cells, which are responsible for producing neutrophils and other types of blood cells. When neutrophil levels are low, the body becomes more susceptible to infection. By increasing the production of neutrophils. Emgrast 300 mcg Injection helps reduce the risk of infection in people with neutropenia.

Safety Advices Emgrast 300 mcg Injection

Kidney

Safe

Liver

Safe

Breastfeeding

Unsafe

Alcohol

Unsafe

Pregnancy

Unsafe

Driving

Safe

References

1. Neupogen (filgrastim) Injection, For Subcutaneous Or Intravenous Use, Producamgen Inc. Product Leaflet 

2. Neupogen 300 Mcg/0.5ml Solution For Injection Pre-filled Syringe, Amgen New Zealand Limited, [date Of Revision 30 November 2022 ], Available Form 

3. Neupogen (filgrastim): General Information For The Public, Centers For Disease Control And Prevention (CDC), Available Form 

4. Neupogen (filgrastim), Amgen Manufacturing, Limited, Product Monograph 

5. Neupogen- Filgrastim Injection, Solution, Daily Med.com, Available Form